Biomea Fusion (BMEA) vs MindWalk (HYFT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
MindWalk (HYFT) has outperformed Biomea Fusion (BMEA) over the past year, losing 17.1% versus a loss of 42.5%. Over five years, HYFT leads with a -78.8% price change compared with -92.1% for BMEA. Biomea Fusion is the larger company by market cap ($62.8 million vs $61.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | HYFT |
|---|---|---|
| Share price | $0.8689 | $1.31 |
| Market cap | $62.82M | $61.72M |
| 1-day change | +3.89% | -6.43% |
| YTD return | -29.93% | -28.02% |
| 1-year return | -42.46% | -17.09% |
| 5-year return | -92.09% | -78.84% |
| EPS (TTM) | $-0.29 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-61.80M | — |
| 52-week high | $2.24 | $2.99 |
| 52-week low | $0.7995 | $0.99 |
| Distance from 52-week high | -61.16% | -56.19% |
| Analyst consensus | buy | none |
| Avg. price target upside | +705.62% | +230.53% |
| Average volume | 1.93M | 239.98K |
| Shares outstanding | 72.30M | 47.11M |
| Employees | 37 | 74 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HYFT has outperformed BMEA by 25.4 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About MindWalk
HYFT stock →MindWalk Holdings Corp. operates as a bio-native AI company.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
BMEA vs HYFT FAQ
Which is bigger, Biomea Fusion or MindWalk?
Biomea Fusion (BMEA) is larger, with a market capitalization of $62.82M compared with $61.72M for MindWalk (HYFT).
Which stock has performed better over the past year, BMEA or HYFT?
HYFT returned -17.09% over the past 12 months, compared with -42.46% for BMEA (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and MindWalk in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.